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1. Introduction 
Human pluripotent stem cells comprise embryonic and induced pluripotent stem cells. Both 
of these are able to give rise to all cell types of an individual, including heart muscle cells or 
cardiomyocytes. First stable human embryonic stem cell (hESC) lines were derived in 1998 
by James A. Thomson and his co-workers (Thomson et al., 1998). First cardiomyocytes 
derived from hESCs were made in 2001 by Kehat and co-workers (Kehat et al., 2001) and 
after that many research groups have derived and studied human pluripotent stem cell 
derived cardiac cells and their properties. In 2007 the first human induced pluripotent stem 
cells (hiPSCs) were produced by Shinya Yamanaka’s (Takahashi et al., 2007)  and James A. 
Thomson’s (Yu et al., 2007) groups from  dermal fibroblasts, and hiPSCs have  subsequently 
also been shown to be able to give rise to cardiomyocytes (Zhang et al., 2009, Zwi et al., 
2009). Pluripotent stem cell derived cardiac cells have a great potential for cardiotoxicity 
testing, for preclinical testing of new chemical entities for the pharmaceutical industry and 
hopefully in the future for cell therapy in myocardial infarction and heart failure. However, 
before these goals are achieved thorough characterization of the cardiomyocytes is needed 
to ensure their feasibility for these applications. 
2. Differentiation of cardiomyocytes from pluripotent stem cells 
Cardiomyocytes can be differentiated from pluripotent stem cells by multiple methods and 
the differentiation event is quite rapid, 10-20 days. However, all the differentiation methods 
have common problems, which include uncontrolled differentiation, low differentiation rate 
and heterogeneous differentiated cell population. In addition, the cardiomyocyte 
differentiation efficiency has been shown to vary markedly between different hESC lines 
(Pekkanen-Mattila et al., 2009). The differentiation methods are described in more detailed 
manner below and summarized in Figure 1.  
2.1 Spontaneous differentiation in embryoid bodies 
Cardiomyocyte differentiation from hESCs and hiPSCs in EBs has been described in many 
reports (Figure 1 A) (Itskovitz-Eldor et al., 2000, Kehat et al., 2001, Burridge et al., 2007, 
Zhang et al., 2009). In addition to cardiomyocyte generation, EB differentiation is widely 
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used also in production of other cell types such as neuronal cells, hematopoietic cells, 
adipocytes and chondrocytes (Pera & Trounson, 2004). For the whole existence of hESCs, EB 
differentiation has been widely used differentiation method for its relatively simple and 
inexpensive nature regardless the low differentiation rate. For example, if aiming at cardiac 
differentiation, under 10% of the EBs formed contain beating areas (Kehat et al., 2001). 
2.2 Differentiation with mouse visceral endoderm –like cells 
A little more directed way to differentiate cardiomyocytes from hESCs is in co-culture with 
mouse endodermal-like (END-2) cells (Figure 1B) (Mummery et al., 2003, Passier et al., 
2005). The differentiation inducing factors are secreted from END-2 cells and therefore 
END-2 conditioned medium can also be used in cardiomyocyte differentiation (Graichen et 
al., 2008). With END-2 methods, cardiogenic differentiation potential can be enhanced with 
serum-free medium supplemented with ascorbic acid (Passier et al., 2005) or adding 
cyclosporine A to the culture medium (Fujiwara et al., 2011). 
END-2 cells support the differentiation towards endodermal and mesodermal derivatives 
(Mummery et al., 2003, Passier et al., 2005, Beqqali et al., 2006). This is in accordance with 
embryonal development studies, which have shown that anterior visceral endoderm is 
essential in normal heart development (Lough & Sugi, 2000).  The specific mechanism or the 
specific factors inducing cardiac differentiation by END-2 cells are, however, not clearly 
known.  It has been suggested that removal of insulin by END-2 cells could have a role in 
this differentiation method. Insulin inhibits cardiac differentiation by suppressing 
endoderm and mesoderm formation and favouring ectoderm differentiation (Freund et al., 
2008) therefore the elimination of insulin from the medium by END-2 cells could favour the 
cardiac differentiation. Additionally, another more promising mechanism inducing cardiac 
differentiation by END-2 cells has been suggested to be prostaglandin I2 (PGI2) (Xu et al., 
2008). 
2.3 Cardiac differentiation with defined growth factors 
The combination of activin A and BMP-4  with matrigel has been used in differentiation 
protocols for cardiomyocytes (Figure 1C) (Laflamme et al., 2007). These factors enhance 
mesoendoderm formation, an early precursor cell lineage which gives rise to mesoderm and 
endoderm (Laflamme et al., 2007). Mesoderm is the origin of cardiac cells , but cardiac 
differentiation inducing signals are in large extent arising from endoderm (Lough & Sugi, 
2000). 
A stepwise differentiation protocol has also been developed by Gordon Keller's group (Yang et 
al., 2008, Kattman et al., 2011). This protocol involves induction of primitive streak-like 
population, in addition to formation of cardiac mesoderm and expansion of cardiac lineages. 
The protocol is based on EB differentiation and is comprised of three stages. Growth factors 
BMP-4, FGF, activin A, vascular endothelial growth factor (VEGF) and dickkoptf homolog 1 
(DKK1) were used in varying combinations. Mesoendoderm formation has also been induced 
by Wnt3A, an activator of the canonical Wnt/┚-catenin signalling pathway (Tran et al., 2009). 
3. Characteristics of differentiated cardiomyocytes 
Cardiac differentiation can be followed by multiple markers at gene and protein expression 
levels. During early stages of differentiation mesoderm formation is detectable by the 
elevated mRNA level of Brachyury T. Brachyury T expression peak is detected at day 3 in 
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END-2 co-cultures (Beqqali et al., 2006, Pekkanen-Mattila et al., 2009) and a day later in EBs 
(Bettiol et al., 2007, Pekkanen-Mattila et al., 2010). The cardiac differentiation cascade can be 
 
 
Fig. 1. Differentiation methods for hESC derived cardiomyocytes (middle column) and 
characteristics of the differentiated cells (undermost column).  EB-differentiation can be 
performed in three ways, EBs can be formed either in hanging drops: enzymatically 
dissociated stem cells are pipetted in suspension into small drops on petri dish which is then 
inverted. EBs form in these drops and they can be plated down afterwards. EBs can be 
formed also in 96-well-plate wells, where single cell suspension is added and EB formation 
is forced by sentrifuging. Traditional was to EB formation is however the suspension method, 
where EBs form spontaneously in suspension from enzymatically dissociated hESCs. The 
picture A represents a 12-day old EB is attached to the bottom of cell culture dish. 
Differentiation with END-2-cells can be performed in two ways; hESC are plated onto END-2 
cell layer and differentiated as co-culture or hESC are differentiated as EBs in END-2 
conditioned medium. The picture B is taken from END-2 co-culture after one week of 
differentiation. Third way presented here is to culture hESCs on matrigel and initiate 
differentiation towrads cardiac lineage with growth factors, such as Activin-A and BMP-4. 
Differentiation is performed in a monolayer of cells (C). 
The first sign for differentiated cardiomyocytes is the formation of beating areas. hESC-CM 
have the ability to contract spontaneously and in addition to fire spontaneously action 
potentials (D). Differentiated cells are stained positively with troponin T (E) and connexin 45 
can be seen in the border areas of two troponin T positive cells (F). Electronmicroscopy (G) 
reveals sarcomere structures with Z-bands (marked with arrows) in the differentiated hESC-
CMs. 
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followed further by the expression of the cardiac regulatory transcription factors such as 
Islet-1 (ISL-1), Mesp 1, GATA-4, NKX2.5 and Tbx6 (Graichen et al., 2008, Yang et al., 2008).   
The first clear indication for emergence of cardiomyocytes is the formation of spontaneously 
beating aggregates or areas in the cell culture dish (Kehat et al., 2001, Mummery et al., 2003). 
The number of beating areas has been used in quantifying differentiation efficiency even 
though the beating areas contain varying numbers of cardiomyocytes (Passier et al., 2005, 
Pekkanen-Mattila et al., 2009, Pekkanen-Mattila et al., 2010). The amount of cardiomyocytes 
has also been quantitated using flow cytometry (Kattman et al., 2011).  Electron microscopy 
studies reveal that the differentiated cardiomyocytes contain myofibrils which are first 
organized randomly throughout the cytoplasm. However, organized sarcomeric structures 
occur at later stages of differentiation with A, I, and Z bands (Figure 1G). In the vicinity of 
the sarcomeres, mitochondria are also present. In addition, cells have intercalated disks with 
gap junctions and desmosomes  (Kehat et al., 2001, Snir et al., 2003, Pekkanen-Mattila et al., 
2009). Cardiac structural proteins such as troponin I, T or C (Figure 1 E), myosins and ┙-
actinin are also present in differentiated beating cells (Kehat et al., 2001, Mummery et al., 
2003). 
The beating function of heart muscle is the result of chain reactions between many ionic 
currents through cell membranes and sarcomeric proteins in the cytoplasm. Cardiomyocytes 
express ion channels and gap junction proteins on the cell membrane and these proteins are 
needed for transmission of electrical stimuli from cell to another (Figure 1 F) (He et al., 2003, 
Sartiani et al., 2007). Furthermore, there are intracellular channels such as ryanodine 
receptor 2 (RyR2) which are responsible for the calcium-induced calcium release (CICR) 
from the sarcoplasmic reticulum (Fabiato, 1983, Dolnikov et al., 2006, Satin et al., 2008). All 
these channels function in a cascade which results in synchronous contraction of the heart 
mediated by sarcoplasmic proteins.    
4. Cardiomyocytes during embryonic development and stem cell 
differentiation 
The development of the heart is composed of series of complicated differentiation events 
and morphogenetic changes (Buckingham et al., 2005). Additionally, electrical activities of 
cardiac cell change during development. For example, the average beating rate of human 
neonatal cardiomyocytes is ~140 beats per minute and in adult cardiomyocytes ~80 beats 
per minute (Huang et al., 2007).  The data of human cardiac embryology is, however, very 
restricted and, thus, most information is based on animal models. Microelectrode recordings 
from chick embryo revealed that the first contracting cardiomyocytes have pacemaker like 
action potentials. According to these measurements, the membrane diastolic potential in the 
first pacemaker like cells is in the range of -35 mV, action potential amplitude is relatively 
small and Ca2+ dependent action potential upstroke is slow (Sperelakis & Shigenobu, 1972). 
Similar postnatal development changes are seen in rabbit models. The beating rate decreases, 
action potential duration increases and the maximal diastolic potential (MDP) reaches more 
negative values during development (Toda, 1980). Allah and co-workers investigated in 
rabbits mRNA levels of several ion channels and Ca2+ handling proteins such as 
hyperpolarization activated cyclic nucleotide-gated potassium channel 4 (HCN4), NaV1.5, 
CaV1.3, NCX 1, KV1.5, ERG, KVLQT1 (also known as KCNQ1) and minK and they observed 
decreased mRNA levels of all these factors and suggested that this could explain the postnatal 
decrease in the beating rate and increase of action potential duration (Allah et al., 2011).   
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Ca-handling in cardiomyocytes also changes during embryonic development. According to 
ultrastructural studies, the sarcoplasmic reticulum is not completely developed at the early 
developmental stages and therefore neonatal cardiomyocytes are suggested to be more 
dependent on transsarcolemmal Ca2+ influx than sarcoplasmic Ca2+ release (Brook et al., 1983, 
Nakanishi et al., 1987, Nassar et al., 1987, Klitzner & Friedman, 1989). Therefore Na+/Ca2+ 
exchanger (NCX) have been suggested to have a important role in excitation-contraction 
coupling during the early developmental stages (Klitzner et al., 1991, Wetzel et al., 1991, 
Wetzel et al., 1991, Huynh et al., 1992) . Indeed, NCX gene and protein expression, in addition 
to NCX current have been shown to be enhanced at the early developmental stages (Artman, 
1992, Artman et al., 1995, Chin et al., 1997, Haddock et al., 1997, Gershome et al., 2011).      
Asp and colleagues compared the cardiac marker and ion channel expression of human 
embryonic stem cell derived cardiomyocyte (hESC-CM) clusters to human fetal, neonatal 
and adult atrial and ventricular origin heart tissue samples (Asp et al., 2010). They found the 
beating frequencies between hESC-CM clusters to vary substantially. They could identify 
two groups, one having slow (< 50 beats per minute[bpm]) and the other high (> 50 bmp) 
beating rate and they suggested these could represent ventricular and atrial type of cardiac 
cells, respectively. They also demonstrated that hESC-CMs had higher NKX2.5 and cardiac 
muscle actin mRNA expression levels than the heart samples. The NKX2.5 expression level, 
however, decreased over time in culture finally approaching that of the heart samples. 
Cardiac troponin T was more strongly expressed in ventricular samples and in hESC-CMs 
compared to atrial samples. The levels of cardiac troponin T mRNA also decreased over 
time in hESC-CMs. Phospholamban was expressed less in the atrial samples and hESC-CMs 
compared to ventricle samples. ┙-myosin heavy chain, which is normally mostly expressed 
in atrial tissue, was more strongly expressed in hESC-CMs with beat rates over 50 bpm and 
in adult atrial tissue samples whereas ┚-myosin heavy chain was more expressed in the 
ventricular heart samples and less in all the other heart preparations of hESC-CMs. The ┙-
myosin heavy chain mRNA levels increased with increasing age of the hESC-CMs. Across 
all the heart tissue and hESC-CM samples cardiac RyR2, L-type calcium channel, and NaV1.5 
sodium channel mRNA were similarly expressed. HERG mRNA expression in hESC-CMs 
was similar to neonatal and adult atrial samples. HCN2 was expressed in a more comparable 
way to the ventricular samples. Only HCN4 expression differed between the hESC-CMs, 
with those having the beating rate of less than 50 bpm having lower expression. Overall,  it 
was concluded that the difference between slow beating and fast beating hESC-CMs 
paralleled the human atrial and ventricular tissues (Asp et al., 2010). Despite small 
differences in expression levels, the conclusion from this study was that stem cell -derived 
cardiac cells share many similarities with human heart tissue and thus stem cell -derived 
cardiac cells are a good cellular model for human heart. 
5. Electrophysiology of human pluripotent stem cell derived cardiomyocytes 
The electrical properties of pluripotent stem cell derived cardiac cells have been studied 
principally either with patch clamp analysis of single cells or with microelectrode array 
(MEA) platform using beating cell aggregates. 
5.1 Patch clamp analysis 
Patch clamp method has been developed to study ion channels in excitable membranes. 
(Sakmann & Neher, 1984). In this technique micropipette is attached to the cell membrane 
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by a giga seal and this can be exploited to measure current changes and voltage across the 
membrane. This technique has been widely used in detailed electrical analysis of pluripotent 
stem cell derived cardiomyocytes. 
Key cardiac ion channel types (and respective currents in brackets) involved in the human 
ventricular action potential include NaV1.5 (INa), KV4.3 (Ito), CaV1.2 (ICa,L) KV11.1 (IKr), KV7.1 (IKs), 
and Kir2.X (IK1) (Pollard et al., 2010). These ion channels mediate the complex interaction 
between the currents and result in the characteristic action potential shape which can be 
divided into five different phases (Figure 2). Phase 0 of the action potential is the 
depolarization of the cardiomyocytes from the negative membrane potential to positive, 
called the upstroke. This is followed by phase 1, the short transient repolarization that is 
followed by phase 2, the plateau at slightly less positive membrane potential than the  
 
 
Fig. 2. Action potential phases and specification of cardiomyocyte subtypes. (A) Action 
potential (AP) parameters: Action potential amplitude (APA), maximum rate of rise of the 
action potential (dV/dtmax), action potential delay (ADP) and membrane diastolic potential 
(MDP). AP phase 0 is a rapid depolarization phase when the sodium channels are activated 
and membrane permeability is increased to Na+. Rapid depolarisation is followed by rapid 
repolarization phase 1 and plateau phase 2, where Ca2+ ions are entered to the cell throught 
L-type calcium channels. At phase 3, calcium channels are inactivated and repolarization is 
caused by outward potassium currents. Repolarization is due to the currents carried mainly 
by the slow Iks and rapid Ikr components of the delayed rectifier potassium channels. The 
Ikr current is produced by hERG channel (encoded by the human ether-à-go-go-related 
gene). By contrast, inward potassium current contributes to the maintenance of the resting 
membrane potential, phase 4. B-D. Classification of ventricular (B), atrial (C) an pacemaker-
like (D) action potentials. Ventricular action potential has a prominent plateau phase 
whereas atrial action potential is more triangularly shaped. Pacemaker-like cells are 
characterized by slower upstroke velocity and amplitude if compared to ventricular and 
atrial type of cells. 
www.intechopen.com
 
Human Pluripotent Stem Cell-Derived Cardiomyocytes: Maturity and Electrophysiology 
 
191 
maximal upstroke value. Phase 2 is followed by phase 3, which is the repolarization back to 
the resting membrane potential. The resting state of the membrane potential is phase 4 
(Nerbonne & Kass, 2005). 
Sartiani and co-workers have investigated the expression of different ion channel proteins 
and respective ion currents with patch clamp technique in undifferentiated hESCs and in 
their early- (days 15 to 40) and late-stage (days 50-110) cardiomyocyte derivates using the 
EB differentiation method (Sartiani et al., 2007). Some ion currents were present readily in 
the undifferentiated cells (IKr, If, Ica,L). The properties of these currents were modified during 
hESC-CM development and some new currents (Ito and IK1) were introduced, so the 
cardiomyocytes achieved maturation over time. With regard to the Ito, transient outward 
potassium current, the two isoforms Kv1.4 and Kv4.3 were differentially expressed in the 
developing cardiomyocytes at mRNA level. The shorter Kv4.3 splice variant was expressed in 
over 57-days-old cardiomyocytes whereas the longer one was expressed in the earlier 
cardiomyocytes. The Kv1.4 isoform is expressed at least from day 25 onward. Despite Kv4.3 
mRNA expression in hESCs Ito current was not present in them. Ito could be detected using 
patch clamp on day 12 in the developing hESC-CMs and it was higher in later-stage (57 days 
old) cardiomyocytes compared to earlier ones (Sartiani et al., 2007).  
Another repolarizing current (IKr), encoded by the human ether-a-go-go related gene 
(HERG) channel is also expressed in hESCs as well as the developing cardiomyocytes. 
However, the shorter splice variant HERG1b mRNA was only expressed in the developing 
hESC-CMs. Using patch clamp an outward K+-current sensitive to E-4031, a selective blocker 
of the IKr current, could also be recorded in hESCs. HCN isoforms encode the If 
depolarization current. HCN1 and HCN4 were expressed more strongly in the 
undifferentiated hESCs and early cardiomyocytes than in late cardiomyocytes. HCN4 was 
also expressed in the adult heart, whereas HCN1 was not. HCN2 was expressed in the adult 
heart as well as strongly in hESCs and early and late hESC-CMs. Voltage clamp experiments 
revealed If currents in hESCs and early and late developing cardiomyocytes. However, 
during cardiomyocyte maturation, the If activation rate decreased. With regard to another 
depolarization current IK1, the Kir2.1 mRNA was already present in hESCs but the current 
could only be measured from the developing cardiomyocytes (Sartiani et al., 2007).   
Voltage-dependent Ca2+ current (ICa,L) is mediated by ┙1C subunit of the calcium channel in 
many tissues and this subunit is encoded by CACNA1C gene.  Sartiani and co-workers 
demonstrated mRNA expression of CACNA1C to be present both in undifferentiated hESCs 
and in the cardiomyocytes. Also, the ICa,L current could be recorded from hESCs as well as 
the hESC-CMs. During hESC-CM development the action potential upstroke velocity and 
action potential duration increased significantly. The beating rate on the other hand 
decreased during cardiomyocyte maturation and the diastolic depolarization rate flattened 
in the late cardiomyocytes. Pharmacological interventions also demonstrated intact ion 
channel function and expected responses were obtained with E4031 and BsCl2 (IK1 blockers), 
zatebradine (If blocker), and lacidipine (ICa,L blocker). Finally, stimulation with isoprenaline 
proved intact ┚-adrenergic signalling in the stem cell derived cardiomyocyte (Sartiani et al., 
2007).  
Taken together, the cardiomyocytes seem to achieve a more mature cardiac phenotype over 
time in cell culture, even though this has not been confirmed in all studies (Pekkanen-
Mattila et al., 2010). The Ito and IK1 currents could serve as markers for hESC cardiac 
differentiation (Sartiani et al., 2007) since they appear only later in cardiac differentiation. Ito 
current has also been shown to increase in postnatal rat cardiomyocytes (Guo et al., 1996, 
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Shimoni et al., 1997) and IK1 current has been shown to stabilize the diastolic potential in 
myocytes (Silva & Rudy, 2003).  
With regard to the EB and END-2 co-culture differentiation methods our own experiments 
demonstrated that the EB method produces slightly more cardiomyocytes with consistent 
beating rate and more cardiomyocytes with ventricular type action potentials. The EB 
method also produced cardiomyocytes with significantly more hyperpolarized MDP 
(Pekkanen-Mattila et al., 2010). Low expression of IK1 current in developing hESC-CMs 
seems to be responsible, at least in part, for their low MDP (Sartiani et al., 2007). 
Cardiomyocytes produced with both methods did not differ in their upstroke velocity 
(Pekkanen-Mattila et al., 2010a).  
Dolnikov and colleagues studied mechanical functions of hESC derived cardiac cells. They 
found that hESC-CMs have a negative force-frequency relation, whereas mature human 
myocardium the relationship is positive (Dolnikov et al., 2005). They also found that 
blocking the ryanodine receptor or the sarcoplasmic-endoplasmic reticulum Ca2+ -ATPase 
did not affect the hESC-CM contraction as it usually does in mature cardiomyocytes. 
Furthermore, caffeine did not result in increase of intracellular calcium concentration. 
However, in subsequent studies caffeine-indused release of intracellular Ca2+  has been 
documented both in hESC and hiPSC -derived cardiac cells (Satin et al., 2008, Itzhaki et al., 
2011). Both RyR mediated release of intracellular Ca2+ stores as well as the reuptake of Ca2+ 
by SERCA into endoplasmic reticulum were reported to occur the same way as in cardiac 
tissue. These results indicate that Ca2+ handling in both hESC and hiPSC-derived cardiac 
cells are functional and further indicate the potential of these cardiac cells in the future 
applications in basic research as well as in translational cardiac research. 
5.2 Microelectrode array platform 
In addition to the more traditional patch clamp (Hamill et al., 1981) studies the MEA 
platform (Reppel et al., 2004) offers an easy and convenient medium-throughput technique 
to assess the electrical properties of the differentiated cardiomyocytes (Reppel et al., 2005). 
Action and field potential curves achieved by patch clamp and by MEA are represented in 
Figure 3. The MEA platform presents an advantageous additional tool for cardiac safety 
studies in addition to the more traditional Langendorff heart organ model, conventional 
patch clamp electrophysiology studies and heterologous expression systems of ion channels, 
especially the hERG potassium channel (Meyer et al., 2004)..  
The MEA system allows examination of multicellular cardiac syncythia, thus enabling 
electrocardiogram-like mapping of their field potential properties. Cardiac repolarization in 
hESC-CMs can be therefore investigated with MEAs and it has been demonstrated that drug 
effects can be investigated using this platform (Reppel et al., 2005). With MEA system, Caspi 
and co-workers were able to investigate drug effects on hESC-CMs. E-4031 is a compound 
that blocks IKr repolarizing current and this effect can be seen as prolongation of the cardiac 
field potential (FP) cycle in the electrocardiogram. The authors were able to demonstrate a 
dose-dependent effect where the field potential duration (FPD) prolonged by escalating 
concentrations of E-4031. Sotalol, a class III antiarrhythmic agent, also increased FPD as did 
quinidine and procainamide, both class IA antiarrhythmic agents. Cisapride, a 
gastrointestinal prokinetic drug that was withdrawn for the market due to adverse cardiac 
side effects, prolonged the FPD as well, as seen on the MEA recordings (Caspi et al., 2009, 
Liang et al., 2010).  
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Fig. 3. Action and field potentials recorded from human embryonic stem cell –derived 
cardiomyocytes. Action potentials can be measured from single cardiomyocytes in current 
clamp mode using the patch clamp technique. Field potentials can be measured from a 
multicellular cardiac syncytium with microelectrode arrays. 
To assess the practicality of using hESC-CMs in conjunction with the MEA platform in 
pharmacotoxicological testing, Braam and colleagues investigated the effects of various 
drugs on the FPD of cardiomyocytes derived from human ES cells (Braam et al., 2010). They 
tested 12 compounds for their potential in prolonging repolarization (FPD) in hESC-CMs. 
Despite the relatively lower maturation of hESC-CMs compared to mature cardiomyocytes, 
they could be used in predicting the clinically observed cardiotoxic effects. Blocking of 
sodium, calcium and HERG potassium channels by lidocaine, nifidipine, and E-4031, 
respectively, had expected effects on hESC-CM field potential properties. Quinidine and 
sotalol, both used clinically to prolong repolarization, increased hESC-CM FPD at 
concentrations near the unbound effective therapeutic plasma concentration (ETCP 
unbound). They also tested drugs which have been known to prolong the QT interval in 
patients and noticed that the FPD prolongations too place at concentrations that were not as 
near the ECTP unbound range. The varying FP shapes in hESC-CM recordings did not affect 
the results, meaning that FPD changes in these cardiomyocytes can be reliably detected 
despite the large variety of FP shapes (Braam et al., 2010). The study provided, for the first 
time, data on the effects of large number of tested compound over a high concentration 
range on the FP properties of hESC-CM. 
6. Applications for pluripotent stem cell-derived cardiomyocytes 
6.1 Human model for development of cardiomyocytes and cardiac electrophysiology 
The amount of data about electrophysiological changes during human cardiac 
differentiation is limited. Data is mostly based on animal models, but due to the 
physiological differences between species this data cannot be always applied directly to 
humans. Human pluripotent stem cells differentiate into functional cardiomyocytes and 
these cells also mature in culture (Sartiani et al., 2007). Therefore they provide a good model 
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to study development of complex network of cardiac ion channels involved in signal 
transduction and cardiomyocyte contraction.  
6.2 Drug screening and safety pharmacology 
Many cardiac and also non-cardiac drugs have been withdrawn from the market because of 
toxic effects on heart and its function. Even though all new chemical entities (NCE) are 
tested according to requirements during drug development process, unforeseen effects such 
as syncope, arrhythmia, sudden death, polymorphic ventricular tachycardia (Torsade de 
pointes [TdP]) are occasionally seen only in clinical trials or when the drug is already on the 
market (Redfern et al., 2003, Roden, 2004, Lexchin, 2005). Pharmaceutical regulatory 
authorities have specified and expanded the requirements for safety testing and recommend 
that tests are done with two mammalian species, one rodent and other nonrodent species. 
Tests include electocardiographic recordings and also histological studies of the heart (ICH, 
2005, ICH, 2005, EMEA, 2008).  
With regard to proarrhythmic potential, the QT interval is the cornerstone of the guidelines 
for the assessment of new chemical compounds (ICH, 2005, ICH, 2005). A number of drugs 
can potentially prolong the QT interval (Fenichel et al., 2004, Roden, 2004), and it is also a 
leading cause for use restriction and market withdrawal (Roden, 2004), the International 
Conference of Harmonization has defined the evaluation of this risk for new chemical 
entities as standard preclinical process (Bode & Olejniczak, 2002, Cavero & Crumb, 2005). 
Delayed rectifier potassium current (IKr) is responsible in part for the repolarization of the 
action potential (Vandenberg et al., 2001, Pollard et al., 2008). Inhibition of this hERG 
channel (KV11.1) and the subsequent inhibition of the IKr, is the predominant basis of drug-
induced QT prolongation and TdP (Hancox et al., 2008; Redfern et al., 2003). Currently a 
number of preclinical models and assays have been employed by pharmaceutical companies 
(Carlsson, 2006, Pollard et al., 2008). These assays include in vivo QT assays, such as ECG 
telemetry of conscious dogs (Miyazaki et al., 2005), and in vitro assays, such as 
repolarization assay, which detects changes in the action potential delay (APD) of cardiac 
tissues (isolated animal Purkinje fibres, papillary muscles or cardiomyocytes) or the hERG 
channel assay where hERG current expressed in heterologous cell system (such as CHO or 
HEK293 cells) or  native IKr is characterized (Finlayson et al., 2004, Martin et al., 2004). 
However, current methods are not fully adequate (Redfern et al., 2003, Lu et al., 2008). They 
are costly and the in vivo assays are ethically questionable because of the large number of 
animals used. Therefore there is a need for an in vitro method based on human cardiac cells 
that would bring additional value and reliability for testing novel pharmaceutical agents. 
Cardiomyocytes derived both from hESC and iPS cells have many potential applications in 
the pharmaceutical industry including target validation, screening and safety 
pharmacology. These cells would serve as an inexhaustible and reproducible human model 
system and preliminary reports of the validation of hESC-CM system already exist (Braam 
et al., 2010, Mandenius et al., 2011).  
6.3 Disease modelling with induced pluripotent stem cell –derived cardiomyocytes 
The hiPSC technology (Takahashi et al., 2007, Yu et al., 2007) presents a great opportunity to 
investigate diseases in cell culture that would otherwise be challenging to study. Although 
the full potential of this method is still to be realized in cardiac research, some preliminary 
results provide encouragement to investigate this path further. 
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One condition that is challenging to study in patients in terms of underlying molecular 
mechanisms is the long QT syndrome (LQTS). This condition can be either genetic or 
acquired as a side effect of using certain therapeutic drugs. The first LQTS modelling using 
hiPSCs was reported in 2010 (Moretti et al., 2010). Pluripotent stem cells were 
reprogrammed from fibroblasts of two family members having LQTS type 1, and cardiac 
cells derived from these hiPSCs with LQT1 genotype had prolonged action potential.  
Additionally increased arrhythmogenicity could be demonstrated with isoproterenol. 
Similar findings have been reported about LQTS type 2 (Itzhaki et al., 2011, Matsa et al., 
2011).  
Cardiomyocytes have also been derived from hiPSCs from a patient with Timothy 
syndrome (Yazawa et al., 2011). These patients have mutation in the CACNA1C gene that 
encodes the CaV1.2 calcium ion channel in humans. The cardiomyocytes having Timothy 
syndrome genotype exhibited irregular contractions and excessive calcium influx as well as 
action potential prolongation, irregularities in the electrical activation and abnormal calcium 
transients in the ventricular-type cardiomyocytes (Yazawa et al., 2011). 
Taken together these results provide optimism for modelling different cardiac disease 
phenotypes in cell culture conditions. This allows for more detailed dissection of the 
pathological pathways and molecular interactions within and between the cells. An 
additional benefit is also the fact that these studies can be now carried out in patient-specific 
cells which provide suitable genomic backgrounds for more optimal comparison between 
the clinical disease phenotype and results obtained in vitro.  
7. Challenges in pluripotent stem cell research 
While human pluripotent stem cells represent a promising new tool for pharmacological 
and toxicological testing and hopefully also for regenerative therapies in the future some 
hurdles remain to be cleared before we can achieve those goals efficiently. With regards to 
hiPSC a question remains how close these cells are to hESCs in their properties. While they 
fulfil the criteria required for pluripotent stem cells, some recent studies suggest that they 
retain some aberrant epigenetic reprogramming compared to ES cells (Lister et al., 2011). 
Both cell types have similar global methylomes, but the reprogrammed iPS cell seem to 
retain some memory of the somatic cell DNA methylation patterns in addition to the 
methylation patterns that are specific for iPSCs (Lister et al., 2011). However, the 
cardiomyocytes differentiated from hiPSCs and hESCs seem to have very similar global 
transcriptomes (Gupta et al., 2010). 
Another issue with both, hESCs and hiPSCs, are the currently suboptimal differentiation 
protocols for desired differentiated cell types. Cardiomyocytes are no exception in this case 
and several protocols for more efficient differentiation have been experimented with. 
Recently, increased yields of cardiomyocytes have been obtained by stage-specific 
optimization of the activin/nodal and bone morphogenetic protein (BMP) signalling 
(Kattman et al., 2011). The directed differentiation protocol of hESC-CMs in a monolayer, 
with activin A and BMP4 supplementation, represents another step forward in creating 
more efficient differentiation methods (Laflamme et al., 2007). In hiPS reprogramming 
omission of c-Myc from the four factor Yamanaka cocktail has been shown to enhance their 
cardiogenic potential (Martinez-Fernandez et al., 2010).  
To achieve better cardiomyocyte differentiation efficiencies with pluripotent stem cells we 
need to gain more insight into the lineage-specification steps that govern the transformation 
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of pluripotent stem cells to committed progenitors and finally to mature differentiated 
cardiomyocytes. For example, ISL1+ cardiac progenitors are able to give rise to 
cardiomyocytes, smooth muscle, and endothelial cell lineages and these progenitor 
populations can be expanded in cell culture (Bu et al., 2009). KDR+ cells derived from 
human embryonic stem cells have also been shown to give rise to cardiac progenitor cells 
(Yang et al., 2008). 
8. Conclusion 
In conclusion, human pluripotent stem cell derived cardiomyocytes have very similar 
electrophysiological properties as human heart tissue and, thus, they have a great potential 
in the future to benefit pharmaceutical and toxicological industry.  Additionally, with these 
cells we are closer than ever before to individualized, patient-specific treatments.  However, 
a lot of basic research is still required before we can utilize the full advantage of human 
pluripotent stem cell –derived cardiac cells. 
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